Results 291 to 300 of about 4,376,584 (354)

Interstitial Lung Diseases

open access: yesLancet, The, 2022
Over 200 interstitial lung diseases, from ultra rare to relatively common, are recognised. Most interstitial lung diseases are characterised by inflammation or fibrosis within the interstitial space, the primary consequence of which is impaired gas exchange, resulting in breathlessness, diminished exercise tolerance, and decreased quality of life ...
Toby Maher, Marlies Wijsenbeek
exaly   +4 more sources

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.

The Lancet Respiratory Medicine, 2020
BACKGROUND The INBUILD trial investigated the efficacy and safety of nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF).
A. Wells   +167 more
semanticscholar   +1 more source

Interstitial lung diseases: an overview

2023
ILDs represent a heterogeneous group of parenchymal lung diseases. Outcomes vary considerably and range from spontaneous reversibility to progressive pulmonary fibrosis. Timely identification and management are crucial for patients' quality of life and survival.
Karampitsakos, Theodoros   +4 more
openaire   +1 more source

Interstitial Lung Diseases

Veterinary Clinics of North America: Small Animal Practice, 2007
Several noninfectious nonneoplastic interstitial lung diseases (ILDs) have been recognized in dogs and cats. Overall, these ILDs are poorly characterized in dogs and cats, although awareness of the conditions based on descriptions of clinical case series may be increasing.
Carol R, Reinero, Leah A, Cohn
openaire   +2 more sources

Home - About - Disclaimer - Privacy